Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer's
disease (AD) and, as such, have become the focus of therapeutic development. Recent …

BACKGROUND The microtubule-associated protein tau has been implicated in the
pathogenesis of Alzheimer's disease and a range of other neurodegenerative disorders …

Microtubules (MTs) play a fundamental role in many vital processes such as cell division
and neuronal activity. They are key structural and functional elements in axons, supporting …

Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase
with a plethora of substrates. As a modulator of several cellular processes, GSK-3 has a …

Microtubule-associated proteins (MAPs) were initially discovered as proteins that bind to
and stabilize microtubules. Today, an ever-growing number of MAPs reveals a more …

Tau protein is implicated in the pathogenesis of Alzheimer's disease (AD) and other
tauopathies, but its physiological function is in debate. Mostly explored in the brain, tau is …

Protein kinases (PKs) have emerged as one of the most intensively investigated drug targets
in current pharmacological research, with indications ranging from oncology to …

Microtubule-associated protein tau is characterized by the fact that it is an intrinsically
disordered protein due to its lack of a stable conformation and high flexibility. Intracellular …

The current clinical trial landscape targeting Alzheimer's disease (AD) is reviewed in the
context of studies completed from 2019 to 2021. This review focuses on available data for …